NCT04655352已完成不适用
Single Center, Clinical Trial Examining the Safety and Tolerability of a Bacillus Subtilis Probiotic in Healthy Adult Volunteers in a Single-Blind Design
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- Occurrence of adverse events
研究概览
简要总结
This study is a single-blind, placebo-lead in design examining the safety and tolerability of a probiotic, Bacillus subtilis MB40. Subjects received a 7-day placebo BID lead-in and a 21-day BID course of Bacillus subtilis MB40. GI questionnaires and Bristol stool charts along with evaluation of any medically significant changes, based on physical examination findings, clinical laboratory tests and vital signs assessments were used to determine the safety and tolerability of MB40.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Normal, healthy adult volunteers aged 18 to 55 years.
- •BMI of 18 to 32 kg/m2 (inclusive)
- •Have no clinically significant findings on screening evaluations (clinical, laboratory)
- •If female, participant is not of child bearing potential, which is defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR
- •Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:
- •Hormonal contraceptives (stable for 1 month) including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- •Double-barrier method
- •Intrauterine devices
- •Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
- •Vasectomy of partner (shown successful as per appropriate follow-up)
- •Able to comprehend and willing to sign an Informed Consent Form (ICF).
排除标准
- •History or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders.
- •Current or recent history (<30 days prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection.
- •Frequent GERD, indigestion, nausea, or vomiting (1 or more days per week).
- •Frequent abdominal pain/cramps or bloating (1 or more days per week).
- •Frequent constipation, diarrhea, or alternating constipation/diarrhea (1 or more days per week).
- •Abdominal pain before bowel movements that is relieved with defecation (most bowel movements).
- •Abdominal complaints often worsened by worry or tension (1 or more days per week).
- •Medical diagnosis of esophagitis, gastritis, ulcers, inflammatory bowel disease, gastrointestinal cancer, celiac disease, or irritable bowel syndrome.
- •Recent gastrointestinal bleeding (hematemesis, hematochezia, melena in past 3 months) or anemia in the past 3 months.
- •Unintentional weight loss of 10 lbs or more in the past 3 months.
- •Screening GI Questionnaire Score of ≥ 4 for any single item.
- •Current clinically significant viral infection
- •History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin
- •Resting heart rate less than 45 bpm or greater than 100 bpm.
- •History of unstable ischemic heart disease or uncontrolled hypertension (blood pressure >150/90 mm Hg)
- •History of stomach or intestinal surgery, except that appendectomy and/or cholecystectomy will be allowed.
- •Presence of a malabsorption syndrome possibly affecting drug/Product absorption (e.g., Crohn's disease or chronic pancreatitis)
- •History of alcoholism or drug addiction within 1 year prior to Screening, or current alcohol or drug use that, in the opinion of the investigator, will interfere with the subject's ability to comply with the dosing schedule and study evaluations.
- •Use of any tobacco-containing or nicotine-containing products (including cigarette, pipe, cigar, chewing tobacco, nicotine patch, or nicotine gum) more frequently than 50 cigarettes per week within 2 months prior to Screening or > 20 per week from screen through the end of the study
- •Current treatment or treatment within 30 days or 5 half-lives (t ½) prior to the first dose of study product with another investigational product or current enrollment in another investigational drug protocol at the time of screening.
- •Use of any over-the-counter, prescription, non-prescription preparations (including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations), within 7 days prior to study entry, unless deemed acceptable by the Investigator.
- •Use of greater that 2 units per day of alcohol-containing or caffeine-containing foods or beverages within 72 hours prior to study entry and throughout the duration of the study.
- •Donation of blood in excess of 500 ml within 4 weeks prior to study entry or of plasma within 2 weeks prior to Screening.
- •Receipt of blood products within 3 months prior to study entry.
- •Subjects who, in the opinion of the investigator, are unable or unlikely to comply with the dosing schedule and study evaluations.
结局指标
主要结局
Occurrence of adverse events
时间窗: 4 weeks
GI Questionnaire and weekly in person assessment of adverse events
次要结局
- Weekly mean of daily frequency of GI symptoms(4 weeks)
- Weekly mean of daily severity of GI symptoms(4 weeks)
研究者
相似试验
已完成
4 期
PDEI Following Mitral Valve Surgery in Patients With Pulmonary HypertensionMitral Valve SurgeryPulmonary HypertensionNCT02378649Dr. Robert Klempfner Heart Rehabilitation Institute60
终止
1 期
To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending DosesObesityNCT01469923AstraZeneca18
已完成
1 期
A Single-Center Study of RO5508887 in Healthy VolunteersHealthy VolunteerNCT01664143Hoffmann-La Roche36
尚未招募
1 期
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic LeukemiaLeukemia, B-cellNCT06209671Beijing Immunochina Medical Science & Technology Co., Ltd.12
已完成
1 期
This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult SubjectsInfections, Respiratory TractNCT01706315GlaxoSmithKline72